Boston Scientific (BSX) Net Income towards Common Stockholders (2009 - 2026)

Boston Scientific has reported Net Income towards Common Stockholders for 18 years, with the latest figure at $907.0 million in Q2 2026.

• Net Income towards Common Stockholders for Q2 2026 came in at $907.0 million, up 13.8% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.7 billion (up 46.71% YoY), and the FY2025 annual result was $2.9 billion, up 56.4% from the prior year.
• Net Income towards Common Stockholders slipped to $907.0 million in Q2 2026, from $1.3 billion in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $1.3 billion in Q1 2026 and troughed at $97.0 million in Q1 2022.
• A 5-year average of $511.8 million and a median of $500.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The widest annual swing landed in 2022, when Net Income towards Common Stockholders sank 70.34%; it then surged 300.79% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $126.0 million in 2022, then surged by 300.79% to $505.0 million in 2023, then gained by 11.88% to $565.0 million in 2024, then climbed by 18.94% to $672.0 million in 2025, then soared by 34.97% to $907.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $907.0 million in Q2 2026, $1.3 billion in Q1 2026, and $672.0 million in Q4 2025.